How David Ho transformed HIV from a terminal diagnosis into a manageable chronic condition
In short: For decades, David Ho has been at the forefront of viral research. His pioneering work in the 1990s shifted the trajectory of the HIV/AIDS epidemic by proving that combination therapy could durably suppress the virus, turning an automatic death sentence into a condition that patients can live with long-term.
David Ho’s career is defined by his relentless pursuit of scientific solutions to viral threats. Since the early days of the AIDS epidemic, he has focused on clinical virology and the molecular mechanics of HIV-1. His team’s pivotal breakthrough came in the mid-1990s when they conducted human studies to understand how HIV replicates in vivo. By elucidating these dynamics, Ho and his colleagues demonstrated that treating the virus early and aggressively with combination antiretroviral therapy could achieve durable control, a discovery that fundamentally altered the prognosis for millions of patients worldwide.
Beyond his work on HIV, Ho has applied his expertise to emerging infectious diseases. Drawing on his experience as an adviser during the 2002–2003 SARS epidemic, he assembled a multi-disciplinary team at Columbia University to combat COVID-19. This effort led to the identification of some of the most potent panels of antibodies against SARS-CoV-2. His lab continues to investigate the pathogenesis of the virus, developing new strategies for testing, treatment, and prevention, including the clinical development of antibodies like VYD2311, which has shown promise in neutralizing various SARS-CoV-2 variants.
Ho’s research remains focused on the future of prevention and eradication. In the field of HIV, his lab has engineered bispecific antibodies, such as 10E8.4/iMab, and is exploring long-acting antiretroviral drugs as pre-exposure prophylaxis. These innovations represent a shift toward more sophisticated, durable interventions. Whether addressing the challenges of HIV-1 or the rapid evolution of coronaviruses, Ho’s work emphasizes the importance of basic science in creating clinical tools that can withstand the complexities of viral adaptation and transmission.
Opens the Intellect+ feed with this card first. Swipe up for the next one.
Sources
- Summary by Intellect · source: Ho Lab
- Also: David Ho
- Also: The monoclonal antibody VYD2311 potently neutralizes dominant and emerging SARS-CoV-2 variants.
To cite this card, link to https://intellectplus.co.uk/app/health-david-ho.
How we source, check and correct cards: Editorial standards.
General information, not professional advice. Spotted an error? Flag the card or see corrections and complaints.
Intellect Plus is a visual educational discovery platform for exploring fascinating facts and ideas. Brain Food, Not Brain Rot. What is Intellect Plus?
Related
More in Medicine · More in Health · Latest · A–Z · All topics
